We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Appendectomy Linked to Higher Risk of Microscopic Colitis

By LabMedica International staff writers
Posted on 23 Jun 2022
Print article
Image: Colonic biopsy with features of collagenous colitis. Trichrome stain highlights irregular subepithelial collagen with entrapment of capillaries and inflammatory cells (Photo courtesy of Catherine E. Hagen, MD)
Image: Colonic biopsy with features of collagenous colitis. Trichrome stain highlights irregular subepithelial collagen with entrapment of capillaries and inflammatory cells (Photo courtesy of Catherine E. Hagen, MD)

The most common symptom of microscopic colitis is chronic, watery, non-bloody diarrhea. Episodes of diarrhea can last for weeks, months, or even years. However, many people with microscopic colitis may have long periods without diarrhea.

Appendectomy has been suggested to cause immunomodulating effects in the colon, and earlier studies have shown an inverse relationship between appendectomy and ulcerative colitis, and celiac disease. A cohort study estimated microscopic colitis (MC) to affect 1 in 115 women and 1 in 286 men and accounts for up to 20% of cases of chronic diarrhea among individuals >65 years of age.

A team of medical scientists led by the Karolinska Institutet (Stockholm, Sweden) examined data from the ESPRESSO cohort on 14,520 patients with microscopic colitis who were matched by sex, age, year of biopsy, and residential county to 69,491 controls without microscopic colitis. Of the patients with microscopic colitis, 9,836 had lymphocytic colitis and 4,684 had collagenous colitis. Patients underwent biopsy for microscopic colitis from 1990 to 2017.

The exposure was previous appendectomy, defined as appendectomy at least one year prior index biopsy demonstrating MC, or matching date in controls. Appendectomy was identified using surgical procedure codes and the NOMESCO system. The nomenclature defining complicated and non-complicated appendicitis is not standardized, therefore, complicated and non-complicated appendicitis was defined with surgical procedure codes in combination with ICD (7-10th revisions) codes.

The investigators reported that almost half of patients were diagnosed with microscopic colitis at ages 50 to 70 (43.2%), and 72% were women. Only 4.3% of patients with microscopic colitis had been diagnosed with another form of IBD. Prior to matching, 7.6% of patients with microscopic colitis and 5.1% of controls underwent an appendectomy ≥1 year earlier. Uncomplicated appendicitis was the most common diagnosis. A post-hoc analysis that stratified patients by age at appendectomy showed similar results across all subgroups.

Among over 14,500 patients, those who previously underwent an appendectomy had an overall higher risk of developing microscopic colitis (adjusted odds ratio [aOR] 1.50, 95% CI 1.40-1.61), and this relationship held true for its subtypes. The risk remained elevated even 10 years after an appendectomy (aOR 1.41, 95% CI 1.30-1.52), and the highest associated risk among patients with complicated appendicitis was seen 5 to 10 years after appendectomy.

The authors concluded that the pathophysiology of microscopic colitis is thought to be associated with a dysregulated immune response in the gut mucosa, in genetically predisposed individuals, and infiltration of T-helper cells 17 (Th17) in the lamina propria of colon has been observed, the and that appendicitis has been linked to upregulation of the Th17 pathway. The study was published on June 15, 2022 in the journal Clinical Gastroenterology and Hepatology.

Related Links:
Karolinska Institutet

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
Ultra-Low Temperature Freezer
iUF118-GX

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.